PCSA vs CASI

Analysts rate Processa Pharmaceuticals, Inc.

(PCSA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Processa Pharmaceuticals, Inc.

(PCSA) delivered a total return of -97. 9%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: PCSA returned -93. 8% versus CASI's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 12β versus Processa Pharmaceuticals, Inc. 's 1. 72β — meaning PCSA is approximately -1500% more volatile than CASI relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Processa Pharmaceuticals, Inc.

grew EPS 89. 3% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Processa Pharmaceuticals, Inc.

(PCSA) is the more profitable company, earning 0. 0% net margin versus -137. 6% for CASI Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCSA leads at 0. 0% versus -138. 8% for CASI. At the gross margin level — before operating expenses — CASI leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CASI (31.

1% yield) pays a dividend. PCSA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Processa Pharmaceuticals, Inc. (PCSA) carries a higher beta of 1. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CASI: -99. 0%, PCSA: -93. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCSA is a small-cap quality compounder stock; CASI is a small-cap income-oriented stock. CASI pays a dividend while PCSA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.